Abstract
Background
In myeloma cast nephropathy, fast reduction of serum free light chain (FLC) levels correlates with renal recovery. Recently, extracorporeal treatments using filters with a high-molecular weight cut-off have been successfully used for FLC removal. However, using these new filters, high cost and elevated albumin leakage are common drawbacks. We studied a new and cheaper therapeutic approach with adsorbent resins to evaluate its efficacy.
Methods
We treated four patients, affected by dialysis-dependent acute kidney injury (AKI) due to biopsy proven de novo FLC myeloma cast nephropathy. Each patient underwent bortezomib chemotherapy and extracorporeal treatment with the supra-hemodiafiltration with endogenous reinfusion (HFR) technique (Supra-HFR, Bellco Mirandola, Modena, Italy). Supra-HFR is a kind of hemodiafiltration that utilizes separated convection, diffusion and adsorption. The sorbent cartridge has a high affinity for FLC (both κ and λ) but is able to re-infuse albumin, avoiding the need for albumin perfusions. Supra HFR treatments (4 h each) were carried out for eight consecutive days and then every other day.
Results
All patients showed a significant reduction of serum FLC, whereas serum albumin concentration remained unchanged. Renal function recovered in three out of four patients.
Conclusions
FLC removal with adsorbent resins represents an effective therapeutic strategy that does not require replacement with albumin .
References
Hutchison CA, Cockwell P, Reid S et al (2007) Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J Am Soc Nephrol 18:886–895
Wratten ML, Sereni L, Lupotti M et al (2004) Optimization of a HFR sorbent cartridge for high molecular weight uremic toxins. G Ital Nefrol 21(Suppl 30):S67–S70
De Nitti C, Giordano R, Gervasio R et al (2001) Choosing new sorbents for endogenous ultrapure infusion fluid: performances, safety and flow distribution. Int J Artif Organs 24:765–776
Wratten ML, Ghezzi PM (2007) Hemodiafiltration with endogenous reinfusion. Contrib Nephrol 150:94–102
Leypoldt JK, Cheung AK, Deeter RB (1997) Single compartment models for evaluating & β2-microglobulin clearance during hemodialysis. ASAIO J 43:904–909
Jagannath S, Durie BG, Wolf J et al (2005) Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Hematol 129:776–783
Sonneveld P, Schmidt-Wolf IG, van der Holt B et al (2012) Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol 30:2946–2955
Dimopoulos MA, Richardson PG, Schlag R et al (2009) VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study. J Clin Oncol 27:6086–6093
Ludwig H, Adam Z, Hajek R et al (2010) Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study. J Clin Oncol 28:4635–4641
Hutchison CA, Bladé J, Cockwell P et al (2012) International kidney and monoclonal gammopathy research group. novel approaches for reducing free light chains in patients with myeloma kidney. Nat Rev Nephrol 8:234–243
Conflict of interest
G.P. is an employee of Bellco srl. The other authors have nothing to declare.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pasquali, S., Iannuzzella, F., Corradini, M. et al. A novel option for reducing free light chains in myeloma kidney: supra-hemodiafiltration with endogenous reinfusion (HFR). J Nephrol 28, 251–254 (2015). https://doi.org/10.1007/s40620-014-0130-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40620-014-0130-8